In this Healthed lecture, Professor Henry Brodaty explains the evidence for the effectiveness of Donanemab in slowing cognitive and functional decline, with the greatest benefit being seen in early-stage patients. In addition, he will discuss the practical aspects of the treatment including patient selection, assessment, referral process as well as how the monthly IV infusions are delivered, monitored, and potential side effects. Professor Brodaty will also address the reality that the effectiveness of donanemab is not universal and careful patient selection and managing expectations is important.

H5N1 avian influenza: Global threats, local preparedness and key risk groups
27:09

Long COVID Part 2 – Treatment
41:27

COVID surge update, booster news, new vaccine and more
29:32